Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluating The Efficacy and Safety of MET097, a Fully-Biased, Ultra Long-Acting GLP-1RA, In People With Overweight or Obesity: A Phase 3, Multi-Center Randomized, Controlled Trial (VESPER-4)

Next Previous
Trial Profile

Evaluating The Efficacy and Safety of MET097, a Fully-Biased, Ultra Long-Acting GLP-1RA, In People With Overweight or Obesity: A Phase 3, Multi-Center Randomized, Controlled Trial (VESPER-4)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MET 097i (Primary)
  • Indications Obesity; Overweight
  • Focus Registrational; Therapeutic Use
  • Acronyms VESPER-4
  • Sponsors Metsera

Most Recent Events

  • 31 Dec 2025 Status changed from planning to recruiting.
  • 13 Nov 2025 According to Pfizer media release, Metsera has been acquired and merged into Pfizer.
  • 28 Jul 2025 According to Metsera media release, the company is on track to initiate the Phase 3 program of MET-097i in late 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top